Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

Summary

The CNBC Investment Committee's final-trades segment features four long stock ideas: Vertex Pharmaceuticals on chart momentum, Kimberly-Clark on an oversold setup with a 5% yield and fading Kenvue/Tylenol concerns, S&P Global on a debt and capital markets cycle pickup, and Exxon Mobil on a breakout the speaker remains long. The segment is brief and focuses on technical setups, catalysts, and market-cycle exposure rather than deep valuation work.

• Final Trades segment includes four bullish stock picks from the Investment Committee.
• Vertex Pharmaceuticals is favored after a roughly 30% recent gain and a constructive chart.
• Kimberly-Clark is highlighted for its 5% yield, oversold condition, and fading Kenvue/Tylenol concerns.
• S&P Global is expected to benefit from stronger debt issuance and capital markets activity.
• Exxon Mobil is a continued long after breaking out and rising materially following prior mentions in November and December.